Healio’s recent FDA news in ophthalmology includes the approval of Enzeevu for neovascular age-related macular degeneration and a rare pediatric disease designation for an X-linked retinoschisis candidate.
Catch up on these stories and more below.
FDA approves Enzeevu, aflibercept biosimilar for neovascular AMD
The FDA approved the Enzeevu 2 mg vial kit and prefilled syringe for intravitreal injection for the treatment of neovascular age-related macular degeneration. Read more.
Gene therapy for X-linked retinoschisis receives rare pediatric disease designation
The FDA granted rare pediatric